1P-LSD In Vitro: What Laboratory Research Reveals

1. What is 1P-LSD and why focus on in vitro data?

1P-LSD (1-propionyl-lysergic acid diethylamide) is a substituted lysergamide derived from LSD by adding a propionyl group at the indole nitrogen (N¹). It was first described in the scientific and forensic literature in the mid-2010s in the context of newly emerging lysergamide research compounds.^[1]

Because formal human studies with this class of compounds are limited and carefully regulated, much of the publicly available scientific information on 1P-LSD comes from non-clinical laboratory work. In vitro systems are especially useful because they allow researchers to:

• Characterize structure and fragmentation patterns for analytical detection.
• Study how 1P-LSD is transformed in biological matrices such as serum and liver fractions.
• Measure interactions with receptors, especially serotonin (5-HT) receptors.
• Explore potential metabolic pathways and candidate biomarkers in a controlled setting.

Readers who want to explore the broader range of compounds discussed in our educational content can review the Chems.ca catalog, which lists research materials together with specification details for laboratory work.

For compound-specific reference information, analytical notes and specification data regarding this molecule, you can also consult our dedicated 1P-LSD 100 mcg blotters reference page.

2. Analytical work: identifying and measuring 1P-LSD

2.1 Early structural and analytical characterization

A key early publication by Brandt and colleagues presented a detailed analytical and behavioural characterization of 1P-LSD and related lysergamides.^[1] The study used chromatographic, mass spectrometric and spectroscopic methods to confirm the structure of 1P-LSD and to document its fragmentation behaviour.

For laboratories, this kind of structural work is foundational: it provides diagnostic fragment ions and retention behaviour that allow 1P-LSD to be distinguished from LSD and other lysergamides in complex samples such as blotter extracts or biological matrices.

2.2 LC-MS/MS quantification and stability in serum and urine

Grumann et al. developed and validated an LC-MS/MS method to quantify 1P-LSD and LSD in human serum and urine, motivated by an intoxication case involving 1P-LSD.^[2] Their in vitro stability experiments revealed several important points:

• Temperature-dependent stability: when samples were stored frozen, 1P-LSD remained relatively stable. At 5 °C or room temperature over several days, however, measurable conversion of 1P-LSD to LSD was observed.
• Matrix effects: conversion was more pronounced in serum than in urine, suggesting a role for serum enzymes.
• Enzymatic contribution: adding sodium fluoride (NaF), which inhibits esterases, significantly reduced the conversion of 1P-LSD to LSD in serum, indicating that enzymatic deacylation contributes substantially to this transformation.

For forensic and clinical laboratories this means that pre-analytical handling can strongly influence the measured 1P-LSD / LSD ratio. Poorly controlled storage conditions may lead to underestimation of 1P-LSD and overestimation of LSD in collected samples.^[2]

2.3 Behaviour during GC-MS analysis

More recent work has examined how acyl-substituted lysergamides behave under gas chromatographic conditions. Stability studies on ALD-52 and 1P-LSD have shown that these compounds can partially convert to LSD during GC-MS analysis, especially when extracted using alcoholic solvents and subjected to a hot injector.^[3]

1P-LSD appears somewhat more stable than some other acyl-lysergamides under these conditions, likely because the propionyl group offers more steric hindrance to hydrolysis. However, the findings still highlight a key analytical point: LC-MS-based methods are generally preferred when laboratories need to distinguish 1P-LSD from LSD with high confidence.

3. In vitro metabolism: transformation into LSD and downstream pathways

3.1 Human serum incubation

In addition to analytical characterization, Brandt et al. performed in vitro incubations of 1P-LSD in human serum at physiological temperature. They observed that LSD appears as a major product over time, suggesting that 1P-LSD is readily deacylated in this matrix.^[1]

This early observation hinted that in biological systems 1P-LSD is likely to be transformed into LSD, which then follows metabolic routes similar to those already described for LSD itself.

3.2 Human liver S9 fractions: detailed metabolite mapping

A more detailed picture comes from work by Wagmann et al., who incubated LSD and multiple N-acyl lysergamides (including 1P-LSD) with pooled human liver S9 (pS9) fractions and characterized the resulting metabolites using high-resolution LC-MS/MS.^[4]

For 1P-LSD, they reported:

• Rapid deacylation of 1P-LSD to LSD as a key early step.
• Formation of multiple downstream metabolites via N-deethylation, N⁶-demethylation, hydroxylation and dihydroxylation.
• Production of metabolites that match known LSD metabolites, including a compound consistent with 2-oxo-3-hydroxy-LSD, a major urinary metabolite of LSD.
• Conjugation reactions (such as glucuronidation) affecting some of the oxidized metabolites.

One important conclusion is that many metabolites formed after 1P-LSD deacylation are structurally identical to those seen after LSD exposure, which can make it difficult to distinguish 1P-LSD intake from LSD intake when only common metabolites are measured.

Wagmann et al. did, however, identify N-deethyl-1P-LSD as a metabolite specific to 1P-LSD within their test panel, making it a potential biomarker for 1P-LSD exposure in suitable samples.^[4]

3.3 Enzyme systems involved

By combining pS9 experiments with investigations of cytochrome P450 (CYP) isoenzymes and inhibition studies, the same research group and others implicated:

• Hydrolases/esterases in serum and liver as key mediators of the deacylation step from 1P-LSD to LSD.
• CYP3A4 and additional CYP isoforms in downstream oxidative transformations such as N⁶-demethylation and other hydroxylation steps.^[4]

3.4 Complementary models: hepatocyte-like cells and zebrafish larvae

Beyond liver S9 fractions, 1P-LSD has also been examined in HepaRG cell cultures (a hepatocyte-like human liver model) and in zebrafish larvae as part of comparative metabolism studies on novel substances.^{[5], [7]} These models often produce a rich panel of metabolites, sometimes matching or exceeding those seen in pS9 experiments, and they can offer insight into whole-organism biotransformation in a more integrated context.

Overall, across serum, liver fractions, liver-like cells and zebrafish, the in vitro evidence is consistent: 1P-LSD is efficiently converted into LSD and then follows metabolic pathways that overlap extensively with those known for LSD.

4. Receptor binding and functional assays

To better understand how 1P-LSD itself interacts with molecular targets, Halberstadt and colleagues examined a panel of lysergamides, including 1P-LSD, using radioligand binding and functional assays at several human serotonin receptor subtypes (5-HT_2A, 5-HT_2B, 5-HT_2C) and related monoamine targets.^[6]

Their main in vitro findings for 1P-LSD were:

• Lower receptor affinity: 1P-LSD displayed reduced affinity at 5-HT₂ receptors compared with LSD, typically lower by about one to two orders of magnitude.
• Weaker functional activity: in calcium-mobilization assays, 1P-LSD showed weaker agonist-like responses relative to LSD at the same receptors.

These results suggest that, as an intact molecule, 1P-LSD is a comparatively weak direct activator of 5-HT₂ receptors in vitro. When this is combined with metabolic studies showing efficient conversion to LSD, a coherent picture emerges in which LSD formed from 1P-LSD is likely the main contributor to strong receptor-level activation in biological systems.

5. In vitro toxicity and safety signals

Specific in vitro toxicity data on 1P-LSD are more limited than the metabolism and receptor literature, but several observations can be drawn from studies that include 1P-LSD as part of broader panels of novel psychoactive substances.

• In comparative NPS metabolism work that includes 1P-LSD, zebrafish larvae and HepaRG cell incubations often produced the widest range of metabolites and showed good agreement with available human data, with the publications focusing primarily on metabolic patterns rather than explicit toxicity endpoints.^{[5], [7]}
• Broader reviews of NPS metabolism and toxicokinetics emphasise analytical detectability and metabolite identification; they do not currently highlight distinctive, severe organ-level toxicity signals specifically for 1P-LSD in standard in vitro models.^[7]

Absence of striking toxicity signals in vitro does not imply that a substance is safe for humans. In vitro models cannot capture complex neuropsychological outcomes, rare idiosyncratic reactions, long-term effects or risks related to behaviour and environment.

6. What in vitro research cannot tell us

In vitro data on 1P-LSD are valuable, but there are clear limitations that should be kept in mind whenever these findings are interpreted.

• No direct information on subjective experience: cultured cells and liver preparations cannot reflect individual psychological responses, mental health history or environmental factors.
• Limited view of long-term effects: most in vitro experiments assess acute exposures of minutes or hours (occasionally days). They do not address repeated use, chronic exposure, or developmental outcomes.
• Polydrug and medication interactions: real-world situations frequently involve other substances or medications that can alter pharmacokinetics or pharmacodynamics; these are rarely modelled comprehensively in vitro.

For these reasons, in vitro 1P-LSD research should be viewed as a tool for understanding chemical and biological mechanisms rather than as a complete risk assessment for real-world use.

7. Practical implications for labs and researchers

Taken together, current in vitro data on 1P-LSD have several practical implications for toxicology and research laboratories.

7.1 Awareness of transformation into LSD

Because 1P-LSD is efficiently deacylated to LSD in serum and liver models, the presence of LSD in biological samples does not automatically exclude prior exposure to 1P-LSD or other N-acyl lysergamides. This is especially relevant in settings where such compounds are known to circulate in the local market.^{[2], [4]}

7.2 Analytical strategy and sample handling

When 1P-LSD exposure is suspected, laboratories may wish to:

• Use LC-MS/MS methods that can differentiate 1P-LSD from LSD and, where possible, target specific metabolites such as N-deethyl-1P-LSD.^{[2], [4]}
• Store samples at low temperatures, protect them from light and consider adding esterase inhibitors such as NaF during collection to reduce artifactual conversion of 1P-LSD to LSD in vitro.^[2]
• Use caution when relying on GC-MS for confirmation, as high injector temperatures and certain solvents may promote deacylation and generate LSD from 1P-LSD during analysis.^[3]

7.3 Interpreting findings in a broader context

Because many metabolites are shared between LSD and 1P-LSD, a comprehensive interpretation of toxicology results often requires:

• Awareness of local patterns in NPS availability.
• Knowledge of the limitations of each analytical method.
• Integration of case history, clinical presentation and other laboratory findings, rather than focusing on a single marker.

9. References

1. Brandt SD, Kavanagh PV, Westphal F, et al. (2016). Return of the lysergamides. Part I: analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). PubMed.
2. Grumann C, Henkel D, Stratmann B, et al. (2019). Validation of an LC-MS/MS method for quantitative analysis of 1P-LSD and LSD in fortified urine and serum including stability tests. PubMed.
3. Zhang SH, Tang ASY, Chin RSL. (2023). Stability studies of ALD-52 and its homologue 1P-LSD. Journal of Forensic Sciences. PubMed.
4. Wagmann L, Richter LHJ, Kehl T, et al. (2019). In vitro metabolic fate of nine LSD-based new psychoactive substances and their detectability in urinary screening procedures. Analytical and Bioanalytical Chemistry. PubMed.
5. Wagmann L, Frankenfeld F, Park YM, et al. (2020). How to study the metabolism of new psychoactive substances for toxicological screenings using pooled human liver S9, HepaRG cells and zebrafish larvae. Frontiers in Chemistry. Full text.
6. Halberstadt AL, Chatha M, Klein AK, et al. (2020). Pharmacological and biotransformation studies of 1-acyl-substituted lysergic acid diethylamide derivatives. Neuropharmacology. Full text.
7. Wagmann L, Gampfer TM, Meyer MR. (2021). Recent trends in drugs of abuse metabolism studies for mass spectrometry–based analytical screening procedures. Analytical and Bioanalytical Chemistry. Publisher.